A survey of prognostic value of serum factors in multiple myeloma patients before treatment: Macrophage-colony stimulating factor (M-CSF) is a powerful predictor of survival

Medical Oncology

Volumn 28, Issue 1, 2011, Pages 194-198

  Kowalska, Maria ^a   Kaminska, Janina ^a   Fuksiewicz, Malgorzata ^a   Kotowicz, Beata ^a   Chechlinska, Magdalena ^a   Druzd Sitek, Agnieszka ^a   Walewski, Jan ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Cytokine; M CSF; Multiple myeloma; Prognostic factor

Indexed keywords

ALBUMIN; BASIC FIBROBLAST GROWTH FACTOR; BETA 2 MICROGLOBULIN; COLONY STIMULATING FACTOR 1; CYTOKINE RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LACTATE DEHYDROGENASE; SOLUBLE INTERLEUKIN 2 RECEPTOR; SOLUBLE INTERLEUKIN 2 RECEPTOR ALPHA; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 1; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RECEPTORS, CYTOKINE; ROC CURVE; SURVIVAL RATE;

EID: 79952246317     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9403-9     Document Type: Article

References (32)

1. McKenna RW, Kyle RA, Kuehl WM, Grogan TM, Harris NL, Coupland RW. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 200-13.
2. PR Greipp J San Miguel BGM Durie, et al. 2005 International staging system for multiple myeloma J Clin Oncol 23 3412 3420 15809451 10.1200/JCO.2005.04.242
3. M Chechlinska M Kowalska J Kaminska 2008 Cytokines as potential tumour markers Expert Opin Med Diag 2 691 711 10.1517/17530059.2.6.691 1:CAS:528:DC%2BD1cXovV2rs7k%3D (Pubitemid 351997857)
4. LA Hefler R Zeillinger C Grimm, et al. 2006 Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer Gynecol Oncol 103 512 517 16750560 10.1016/j.ygyno.2006.03.058 1:CAS:528: DC%2BD28XhtFegur7J (Pubitemid 44740099)
5. H Bozcuk G Uslu M Samur, et al. 2004 Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy Cytokine 27 58 65 15242694 10.1016/j.cyto.2004.04.002 1:CAS:528:DC%2BD2cXlsFyhsro%3D (Pubitemid 38881527)
6. I Zlobec T Vuong S Hayashi, et al. 2007 A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy Br J Cancer 96 793 800 17311026 10.1038/sj.bjc.6603619 1:CAS:528:DC%2BD2sXisVGisrc%3D (Pubitemid 46376624)
7. J Kaminska M Kowalska B Kotowicz M Fuksiewicz M Głogowski E Wójcik M Chechlińska J Steffen 2006 Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis Oncology 70 115 125 16645324 10.1159/000093002 1:CAS:528:DC%2BD28XkslWgurc%3D (Pubitemid 43760337)
8. B Mroczko M Groblewska U Wereszczynska-Siemiatkowska B Okulczyk B Kedra W Laszewicz A Dabrowski M Szmitkowski 2007 Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis Clin Chim Acta 380 208 212 17368603 10.1016/j.cca.2007.02. 037 1:CAS:528:DC%2BD2sXjslSlurY%3D (Pubitemid 46498063)
9. R Stasi M Brunetti A Parma C Di Giulio E Terzoli A Pagano 1998 The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma Cancer 82 1860 1866 9587117 10.1002/(SICI)1097-0142(19980515)82: 10<1860::AID-CNCR7>3.0.CO;2-R 1:STN:280:DyaK1c3ks1Gntg%3D%3D (Pubitemid 28208640)
10. TT Pelliniemi K Irjala K Mattila K Pulkki A Rajamäki A Tienhaara M Laakso R Lahtinen 1995 Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group Blood 85 765 771 7530507 1:CAS:528:DyaK2MXjtlCqtbk%3D
11. T Iwasaki T Hamano A Ogata N Hashimoto M Kitano E Kakishita 2002 Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma Br J Haematol 116 796 802 11886383 10.1046/j.0007-1048. 2002.03364.x 1:CAS:528:DC%2BD38XislOqu7o%3D (Pubitemid 34226998)
12. NF Andersen T Standal JL Nielsen L Heickendorff M Borset FB Sørensen N Abildgaard 2005 Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival Br J Haematol 128 210 217 15638855 10.1111/j.1365-2141.2004.05299.x 1:CAS:528:DC%2BD2MXhs1Grsr0%3D
13. H Urbanska-Rys A Wierzbowska H Stepien T Robak 2000 Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma Eur Cytokine Netw 11 3 443 451 11022130 1:CAS:528:DC%2BD3cXotFKqtr4%3D (Pubitemid 32268904)
14. O Sezer C Jakob J Eucker K Niemöller F Gatz K Wernecke K Possinger 2001 Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma Eur J Haematol 66 83 88 11168514 10.1034/j.1600-0609. 2001.00348.x 1:CAS:528:DC%2BD3MXhtlalt7o%3D (Pubitemid 32154100)
15. MG Alexandrakis FH Passam A Boula A Christophoridou G Aloizos P Roussou DS Kyriakou 2003 Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma Ann Hematol 82 19 23 12574959 1:CAS:528:DC%2BD3sXpslSquw%3D%3D (Pubitemid 36700965)
16. X Filella J Blade AL Guillermo R Molina C Rozman AM Ballesta 1996 Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma Cancer Detect Prev 20 52 56 8907203 1:STN:280:DyaK2s%2Fmtlegtw%3D%3D (Pubitemid 2627095)
17. C Pappa S Miyakis G Tsirakis A Sfiridaki A Alegakis M Kafousi EN Stathopoulos MG Alexandrakis 2007 Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma Cytokine 37 171 175 17446083 10.1016/j.cyto.2007.02.022 1:CAS:528:DC%2BD2sXlt1alur8%3D (Pubitemid 46694336)
18. WP Arend M Malyak CJ Guthridge C Gabay 1998 Interleukin-1 receptor antagonist: role in biology Annu Rev Immunol 16 27 55 9597123 10.1146/annurev.immunol.16.1.27 1:CAS:528:DyaK1cXislyitr4%3D (Pubitemid 28183358)
19. A Diez-Ruiz GP Tilz R Zangerle G Baier-Bitterlich H Wachter D Fuchs 1995 Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis Eur J Haematol 54 1 8 7859870 10.1111/j.1600-0609.1995.tb01618.x 1:CAS:528:DyaK2MXksFeitbg%3D
20. M Jourdan K Tarte E Legouffe J Brochier JF Rossi B Klein 1999 Tumor necrosis factor is a survival and proliferation factor for human myeloma cells Eur Cytokine Netw 10 65 70 10210775 1:CAS:528:DyaK1MXjs12iu7Y%3D (Pubitemid 29158740)
21. F Di Raimondo MP Azzaro G Palumbo S Bagnato G Giustolisi P Floridia G Sortino R Giustolisi 2000 Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood Haematologica 85 800 805 10942925 1:STN:280:DC%2BD3M%2FksFyksw%3D%3D
22. J Kaminska M Nowacki M Kowalska A Rysińska M Chwaliński M Fuksiewicz W Michalski M Chechlińska 2005 Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: Soluble necrosis factor receptor type I-an independent prognostic factor Tumor Biol 26 186 194 10.1159/000086951 1:CAS:528:DC%2BD2MXpvVSmsLg%3D (Pubitemid 41379744)
23. C Jakob J Sterz I Zavrski U Heider L Kleeberg C Fleissner M Kaiser O Sezer 2006 Angiogenesis in multiple myeloma Eur J Cancer 42 1581 1590 16797965 10.1016/j.ejca.2006.02.017 1:CAS:528:DC%2BD28Xns1Grt7k%3D (Pubitemid 44118769)
24. F Silvestris L Lombardi M De Matteo A Bruno F Dammacco 2007 Myeloma bone disease: pathogenetic mechanisms and clinical assessment Leuk Res 31 129 138 16764925 10.1016/j.leukres.2006.04.014 1:CAS:528:DC%2BD28Xht12ks7bL (Pubitemid 44854187)
25. L Fang J Fang CQ Chen 2001 TNF receptor-associated factor-2 binding site is involved in TNFR75-dependent enhancement of TNFR55-induced cell death Cell Res 11 217 222 11642407 10.1038/sj.cr.7290090 1:STN:280:DC%2BD3Mrmt1yitg%3D%3D (Pubitemid 33677252)
26. S Gupta 2002 Tumor necrosis factor-alpha-induced apoptosis in T cells from aged humans: a role of TNFR-I and downstream signaling molecules Exp Gerontol 37 293 299 11772515 10.1016/S0531-5565(01)00195-4 1:CAS:528: DC%2BD38XitlGg (Pubitemid 34073546)
27. P Rutkowski J Kaminska M Kowalska W Ruka J Steffen 2003 Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis J Surg Oncol 84 151 159 14598359 10.1002/jso.10305 1:CAS:528:DC%2BD3sXpsF2lsrg%3D (Pubitemid 37363158)
28. M Abe K Hiura J Wilde A Shioyasono K Moriyama T Hashimoto S Kido T Oshima H Shibata S Ozaki D Inoue T Matsumoto 2004 Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion Blood 104 2484 2491 15187021 10.1182/blood-2003-11-3839 1:CAS:528:DC%2BD2cXovVegtLc%3D (Pubitemid 39331851)
29. H Chen RA Campbell Y Chang M Li CS Wang J Li E Sanchez M Share J Steinberg A Berenson D Shalitin Z Zeng D Gui P Perez-Pinera RJ Berenson J Said B Bonavida TF Deuel JR Berenson 2009 Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis Blood 113 9 1992 2002 19060246 10.1182/blood-2008-02-133751 1:CAS:528:DC%2BD1MXivVaqtr8%3D
30. EY Lin AV Nguyen RG Russell JW Pollard 2001 Colony stimulating factor 1 promotes progression of mammary tumors to malignancy J Exp Med 193 727 739 11257139 10.1084/jem.193.6.727 1:CAS:528:DC%2BD3MXitFKhsLo%3D (Pubitemid 32524466)
31. E Richardsen RD Uglehus J Due C Busch LT Busund 2008 The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma Histopathol 53 30 38 10.1111/j.1365-2559.2008.03058.x 1:STN:280:DC%2BD1cvktVegsw%3D%3D (Pubitemid 351861980)
32. Y Kubota K Takubo T Shimizu H Ohno K Kishi M Shibuya H Saya T Suda 2009 M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis J Exp Med 206 5 1089 1102 19398755 10.1084/jem.20081605 1:CAS:528:DC%2BD1MXlvVGmurk%3D